KELOWNA, BRITISH COLUMBIA -- (MARKET WIRE) -- May 10, 2007 -- Sernova Corp. (TSX VENTURE: SVA), a company focused on a novel treatment for insulin-dependent diabetes using its patented Sertolin cell technology, announced that it has raised $2.4 million through the exercise of all outstanding warrants. The funds will be used to continue the Company’s development of Sertolin, Sernova’s cellular therapy for diabetes.
